Asimov has raised $185.0M in total across 2 funding rounds.
Asimov's investors include 7percent Ventures, Alumni Ventures, Andreessen Horowitz, Blockchain.com Ventures, Deerfield Management, Faction VC, Galaxy Interactive, NGC Ventures, Oyster Ventures, Pillar VC, Sunset Ventures, VZVC.
Asimov is a Boston-based biotechnology company founded in 2017 that builds an end-to-end platform for programming living cells through synthetic biology, computer-aided design (CAD), and machine learning.[1][3][4] It provides engineered host cells, genetic parts libraries, and cloud-based design software to enable the production of biologics (like proteins at 8-12 g/L titers via CHO Edge) and cell/gene therapies (like lentiviral vectors at up to 1E9 TU/mL via LV Edge), serving biotech firms developing advanced therapeutics.[1][4] The company solves the challenge of unreliable genetic engineering by standardizing biology like CAD standardized architecture, facilitating faster design, simulation, optimization, and GMP-scale manufacturing of complex therapies.[3][4] With $204.7M raised (including a $175M Series B), Asimov shows strong growth momentum through partnerships like its 2025 collaboration with Cytiva for cell line development and process optimization.[1]
Asimov emerged from academic roots in synthetic biology labs: co-founders Chris Voigt (MIT) and Doug Densmore (Boston University) collaborated on genetic logic circuits to program cells, joined by PhD student Alec Nielsen (now CEO) in the Voigt lab.[3] In 2017, Voigt, Densmore, Nielsen, and Raja Srinivas founded the company to create advanced genetic design tools, inspired by their work on Cello—a system blending lab synthetic biology with computation—securing early funding from Andreessen Horowitz and DARPA.[3] Pivotal early traction included integrating the MIT-Broad Foundry in 2023 (a DARPA-backed genetic design institute from 2013), supercharging R&D, and expanding to GMP-ready platforms for therapeutics.[1][3] Today, headquartered in Boston with ~95 employees and an office in Boulder, Asimov operates its own labs to refine tools used internally and by partners.[3][5]
Asimov rides the synthetic biology wave, transforming genetic engineering into an engineering discipline amid booming demand for biologics and gene therapies, where traditional low-titer cell lines limit complex modalities.[1][3] Timing is ideal: advances in AI/ML for biology design coincide with a $100B+ biologics market and regulatory pushes for faster GMP production, amplified by post-pandemic biomanufacturing investments.[1][4] Market forces like talent shortages in genetic design and need for verifiable, high-yield platforms favor Asimov, influencing the ecosystem by partnering with giants (e.g., Cytiva) and foundries to standardize tools, accelerating therapeutic innovation from research to clinic.[1][3]
Asimov is poised to dominate synthetic biology infrastructure, with its CAD-for-biology platform enabling the next generation of high-complexity therapies amid AI-bio convergence.[3][4] Upcoming trends like AI-optimized multi-omic modeling and Web3-tracked provenance could expand its edge, potentially through more foundry integrations or IPO paths given $200M+ funding and partnerships.[1][3] Its influence may evolve from tool provider to ecosystem orchestrator, powering scalable manufacturing that cuts development timelines—cementing its role as the foundational layer for programmable medicine, much like early CAD reshaped engineering.[3]
Asimov has raised $185.0M across 2 funding rounds. Most recently, it raised $180.0M Series B in January 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2023 | $180.0M Series B | 7percent Ventures, Alumni Ventures, Andreessen Horowitz, Blockchain.com Ventures, Deerfield Management, Faction VC, Galaxy Interactive, NGC Ventures, Oyster Ventures, Pillar VC, Sunset Ventures, VZVC, George Godula, Julian Shapiro, Kevin Colas, Sahin Boydas | |
| Dec 1, 2017 | $5.0M Seed | 7percent Ventures, Alumni Ventures, Blockchain.com Ventures, Faction VC, Galaxy Interactive, NGC Ventures, Oyster Ventures, Pillar VC, Sunset Ventures, VZVC, George Godula, Julian Shapiro, Kevin Colas, Sahin Boydas |
